Johnson & Johnson Scores EU Approval for Tecvayli in Relapsed Multiple Myeloma

Johnson & Johnson (JNJ) has received European Commission approval for Tecvayli (teclistamab) plus daratumumab as a treatment for adult patients with relapsed or refractory multiple myeloma. This expanded label adds a new therapeutic option to Johnson & Johnson's multiple myeloma portfolio and may influence its European oncology franchise over time.

The decision extends the approved indication for Tecvayli in Europe following Phase 3 data that showed significant survival benefits versus standard of care. This approval aligns with Johnson & Johnson's Narrative, which focuses on next-generation therapies in oncology and immunology to support its Innovative Medicine segment.

Investors tracking Johnson & Johnson and broader oncology trends may also want to review peers gaining traction in healthcare-focused AI through 41 healthcare AI stocks. The European Commission approval moves Tecvayli plus daratumumab into earlier line use for relapsed or refractory multiple myeloma in adults, which widens the potential treated population in Europe.